Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 11.08 12.49% 1.23
SYRS closed up 12.49 percent on Friday, August 16, 2019, on 1.74 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SYRS trend table...

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength 12.49%

Older signals for SYRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Diseases Disease Medication Leukemia Refractory Acute Myeloid Leukemia Immune Mediated Diseases Acute Leukemia High Risk Myelodysplastic Syndrome
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.16
52 Week Low 5.17
Average Volume 179,992
200-Day Moving Average 7.2562
50-Day Moving Average 7.7668
20-Day Moving Average 8.3195
10-Day Moving Average 9.055
Average True Range 0.7039
ADX 31.57
+DI 39.7981
-DI 7.9614
Chandelier Exit (Long, 3 ATRs ) 9.0483
Chandelier Exit (Short, 3 ATRs ) 9.0217
Upper Bollinger Band 10.3725
Lower Bollinger Band 6.2665
Percent B (%b) 1.17
BandWidth 49.353928
MACD Line 0.6331
MACD Signal Line 0.3671
MACD Histogram 0.266
Fundamentals Value
Market Cap 290.96 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -5.25
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.51
Resistance 3 (R3) 13.27 12.21 13.11
Resistance 2 (R2) 12.21 11.59 12.34 12.97
Resistance 1 (R1) 11.65 11.21 11.93 11.89 12.83
Pivot Point 10.59 10.59 10.74 10.72 10.59
Support 1 (S1) 10.03 9.97 10.31 10.27 9.33
Support 2 (S2) 8.97 9.59 9.10 9.19
Support 3 (S3) 8.41 8.97 9.06
Support 4 (S4) 8.65